Document is current
Any future updates will be listed below
-
Authors
Torlakovic, Emina E. https://orcid.org/0000-0003-1856-9804
Al Dieri, Raed
Badrick, Tony
Chen, Zongming Eric
Cheung, Carol C.
Deans, Zandra
Dodson, Andrew
Fenizia, Francesca
Kijima, Hiroshi
Maas, Joerg
Martinez, Antonio
Nielsen, Søren
Patton, Simon
Rouleau, Etienne
Schirmacher, Peter
Shet, Tanuja
Stockley, Tracy
Normanno, Nicola
- License Information
-
More Information
Article History
Received: 23 May 2025
Revised: 23 June 2025
Accepted: 24 June 2025
First Online: 17 July 2025
Declarations
:
: This is not applicable, since no patients were included.
: Emina E. Torlakovic declares the following conflicts of interest: advisory board member: Boehringer Ingelheim, AbbVie; presentations/lectures: AstraZeneca, Agilent; operational and educational grants for CBQA: Roche, Merck, BMS, Pfizer, Eli Lilly, AstraZeneca, and Incyte. Carol C. Cheung declares the following conflicts of interest: advisory board participant/consultant/speaker: Abbvie, Agilent Technologies, Astellas Pharma, AstraZeneca, Bayer, Boehringer-Ingelheim, Merck, Pfizer, Roche, and Sanofi-Aventis. Simon Patton declares the following conflicts of interest: personal financial interests (speaker’s fee/advisory boards): AstraZeneca, Novartis-Institutional financial interests (financial support to research projects): AstraZeneca, Diaceutics, MSD, Amgen, Novartis, Janssen, and Johnson & Johnson; and non-financial interests: Chair, External Advisory Committee, International Quality Network for Pathology (IQN Path), Executive Board member of EMQN CIC. Etienne Rouleau declares the following conflicts of interest: boards/oral presentation: AstraZeneca, BMS, Roche, GSK, Clovis, MSD—travel: GSK, AstraZeneca—research: AstraZeneca. Tracy Stockley received honoraria from AstraZeneca and Janssen for advisory board participation. Nicola Normanno declares the following conflicts of interest: speaker’s fee and/or advisory boards from MSD, Bayer, Biocartis, Illumina, Incyte, Roche, BMS, Merck, Thermofisher, AstraZeneca, and Eli Lilly; financial support to research projects (institutional grants) from Merck, Thermofisher, QIAGEN, Roche, AstraZeneca, Biocartis, and Illumina; and non-financial interests: President of the International Quality Network for Pathology (IQN Path). The other authors declare no financial or non-financial existing or potential conflicts of interest that are directly or indirectly related to the work submitted for publication.
